EODData

MEMBERSHIP REGISTER LOG IN

FRA, IF0: InflaRx N.V

23 Dec 2025
LAST:

0.9380

CHANGE:
 0.00		OPEN:
0.9380		HIGH:
0.9380		ASK:
0.0000		VOLUME:
1.2K
CHG(%):
0.48		PREV:
0.9335		LOW:
0.9380		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Dec 250.93800.93800.93800.93801.2K
22 Dec 250.93350.93350.93350.93351.2K
19 Dec 250.89000.89000.89000.89001.2K
18 Dec 250.85250.85250.85250.85251.2K
17 Dec 250.87500.93100.87500.93101.2K
16 Dec 250.80650.87000.80650.870010
15 Dec 250.88400.88400.88400.8840400
12 Dec 250.86750.86750.86750.8675400
11 Dec 250.88900.90000.88900.9000400
10 Dec 250.91050.93000.87150.9100400

PROFILE

Name:InflaRx N.V
About:InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Sector:Healthcare
Industry:Biotechnology
Address:Winzerlaer Str. 2, Jena, Germany, 07745
Website:https://www.inflarx.de
ISIN:NL0012661870

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.44 
Forward P/E:-0.79 
PEG Ratio:0.12 
Price to Sales:495.02 
Price to Book:1.33 
Profit Margin:-19.01 
Operating Margin:-350.91 
Return on Assets:-0.39 
Return on Equity:-0.65 
Revenue:162.8K 
Shares:67.75M 
Market Cap:63.55M 

TECHNICAL INDICATORS

MA5:0.913.2%
MA10:0.904.5%
MA20:0.922.0%
MA50:1.0410.6%
MA100:1.028.8%
MA200:0.984.9%
STO9:100.00 
STO14:100.00 
RSI14:54.73
MTM14:0.12
ROC14:0.14 
ATR:0.05 
Week High:0.940.0%
Week Low:0.8116.3%
Month High:1.1219.7%
Month Low:0.814.9%
Year High:2.62178.9%
Year Low:0.6349.4%
Volatility:161.03